1
Clinical Trials associated with CD22-CART(Zhujiang Hospital of Southern Medical University) / RecruitingEarly Phase 1IIT Sequential Treatment With CD20/CD22/CD10-CART After CD19-CART Treatment Base on MRD in Relapsed/Refractory B-ALL
CD19-negative B-ALL relapses after CD19 CAR T-cell treatment have occurred in some patients. CD20/CD22/CD10 is still expressed in CD19 negative B-ALL cells which means these CD molecules may become new targets in treatment of CD19-negative relapse of B-ALL. Thus sequential treatment with CD20/CD22/CD10-CART after CD19-CART treatment in relapsed/refractory B-ALL will kill and eliminate CD19 negative B-ALL cells and prolong the remission time.
100 Clinical Results associated with CD22-CART(Zhujiang Hospital of Southern Medical University)
100 Translational Medicine associated with CD22-CART(Zhujiang Hospital of Southern Medical University)
100 Patents (Medical) associated with CD22-CART(Zhujiang Hospital of Southern Medical University)
100 Deals associated with CD22-CART(Zhujiang Hospital of Southern Medical University)